Valuation: Rani Therapeutics Holdings, Inc.

Market Cap 87.63M 76.9M 72.62M 66.18M 124M 8.4B 125M 869M 337M 4.29B 329M 322M 13.79B P/E 2026 *
-4.38x
P/E 2027 * -4x
Enterprise Value 87.63M 76.9M 72.62M 66.18M 124M 8.4B 125M 869M 337M 4.29B 329M 322M 13.79B EV / Sales 2026 *
14x
EV / Sales 2027 * 13.2x
Free-Float
4.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week-11.93%
Current month-11.08%
1 month-9.77%
3 months+3.17%
6 months-29.70%
Current year-43.76%
1 week 0.73
Extreme 0.7306
0.87
1 month 0.73
Extreme 0.7306
0.9
Current year 0.61
Extreme 0.6126
1.54
1 year 0.45
Extreme 0.4453
3.87
3 years 0.39
Extreme 0.387
8.75
5 years 0.39
Extreme 0.387
36.27
10 years 0.39
Extreme 0.387
36.27
Manager TitleAgeSince
Chief Executive Officer 45 2021-05-31
Director of Finance/CFO 46 2026-06-28
Chief Tech/Sci/R&D Officer 42 2021-12-31
Director TitleAgeSince
Chairman 69 2021-05-31
Director/Board Member 80 2018-08-31
Director/Board Member 69 2021-04-05
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Director

247,200 0.2479%
8/1/26 Other

Director

12,500 0.0125%
7/21/26 Buy

Founder

36,000 0.0361%
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%-11.93%+58.17%-74.26% 87.63M
-3.30%+1.50%+57.79%+99.14% 72.26B
+1.25%-3.01%+37.83%+87.66% 60.24B
+2.12%+5.26%+35.69%+23.40% 27.73B
-3.06%-1.81%-14.01%+357.24% 25.73B
-0.75%+2.56%+0.45%-3.28% 24.75B
+0.40%+0.75%+23.72%-11.33% 20.74B
-1.70%-2.12%+150.24%+326.97% 15.06B
+0.36%-0.34%+48.98%+167.40% 14.41B
+0.21%+1.17%-3.95%+512.06% 14.23B
Average -0.31%-0.80%+39.49%+148.50% 27.52B
Weighted average by Cap. -0.77%+0.31%+38.17%+132.93%

Financials

2026 *2027 *
Net sales 6.26M 5.49M 5.19M 4.73M 8.85M 600M 8.91M 62.06M 24.04M 306M 23.49M 22.99M 985M 6.63M 5.82M 5.5M 5.01M 9.38M 636M 9.44M 65.78M 25.48M 325M 24.9M 24.36M 1.04B
Net income -31.46M -27.61M -26.07M -23.76M -44.48M -3.02B -44.8M -312M -121M -1.54B -118M -116M -4.95B -36.73M -32.23M -30.44M -27.74M -51.92M -3.52B -52.3M -364M -141M -1.8B -138M -135M -5.78B
Net Debt - -
Logo Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Employees
70
Date Price Change Volume
26-09-25 US$0.7592 +1.36% 382,619
26-09-24 US$0.7490 -2.35% 607,394
26-09-23 US$0.7670 -1.40% 648,575
26-09-22 US$0.7779 -1.46% 652,027
26-09-21 US$0.7894 -8.42% 681,298
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7592USD
Average target price
7.200USD
Spread / Average Target
+848.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RANI Stock